Simultaneous Population Pharmacokinetic Model for Lopinavir and Ritonavir in HIV-Infected Adults

被引：0
作者：
José Moltó
Manuel José Barbanoj
Cristina Miranda
Asunción Blanco
José Ramón Santos
Eugenia Negredo
Joan Costa
Pere Domingo
Bonaventura Clotet
Marta Valle
机构：
[1] Hospital Universitari Germans Trias i Pujol,“Lluita contra la SIDA” Foundation
[2] Universidad Autonóma de Barcelona,Centre d’Investigació del Medicament
[3] Institut de Recerca de l’Hospital de la Santa Creu i Sant Pau,“IrsiCaixa” Foundation
[4] Hospital Universitari Germans Trias i Pujol,Department of Clinical Pharmacology
[5] Hospital Universitari Germans Trias i Pujol,Department of Internal Medicine
[6] Hospital de la Santa Creu i Sant Pau,Fundació Lluita contra la SIDA
[7] Hospital Universitari Germans Trias i Pujol,undefined
来源：
Clinical Pharmacokinetics | 2008年 / 47卷
关键词：
Ritonavir; Lopinavir; Population Pharmacokinetic Model; Objective Function Value; Advanced Liver Fibrosis;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Background: Lopinavir is a protease inhibitor indicated for the treatment of HIV infection. It is coformulated with low doses of ritonavir in order to enhance its pharmacokinetic profile. After oral administration, plasma concentrations of lopinavir can vary widely between different HIV-infected patients.
引用
收藏
页码：681 / 692
页数：11
相关论文
共 121 条
[1]  
Walmsley S.(2007)Protease inhibitor-based regimens for HIV therapy: safety and efficacy J Acquir Immune Defic Syndr 45 S5-S13
[2]  
Sham H.L.(1998)ABT-378, a highly potent inhibitor of the human immunodeficiency virus protease Antimicrob Agents Chemother 42 3218-24
[3]  
Kempf D.L.(2004)Long-term safety and durable antiretroviral activity of lopinavir/ritonavir in treatment-naive patients: 4 year follow-up study AIDS 18 775-9
[4]  
Molla A.(2002)Analysis of the virological response with respect to baseline viral phenotype and genotype in protease inhibitor-experienced HIV-1-infected patients receiving lopinavir/ritonavir therapy Antivir Ther 7 165-74
[5]  
Hicks C.(2002)The protease inhibitor ritonavir inhibits the functional activity of the multidrug resistance related-protein 1 (MRP-1) AIDS 16 1743-7
[6]  
King M.S.(2003)A review of low-dose ritonavir in protease inhibitor combination therapy Clin Infect Dis 36 1585-92
[7]  
Gulick R.M.(2004)Pharmacokinetic enhancement of protease inhibitor therapy Clin Pharmacokinet 43 291-310
[8]  
Kempf D.J.(2006)Updated guideline to perform therapeutic drug monitoring for antiretroviral agents Reviews in Antiviral Therapy 3 4-14
[9]  
Isaacson J.D.(2006)Variability in non-nucleoside reverse transcriptase and protease inhibitor concentrations among HIV-infected adults in routine clinical practice Br J Clin Pharmacol 62 560-6
[10]  
King M.S.(2006)A retrospective TDM database analysis of interpatient variability in the pharmacokinetics of lopinavir in HIV-infected adults Ther Drug Monit 28 650-3
12345678910